Showing results (381-390 of 407) with videos related to
Sort By:
Pageof 41
Parkinsonism & Related Disorders|March 31, 2015
Genetic markers of Restless Legs Syndrome in Parkinson diseaseZiv Gan-Or, Roy N Alcalay, Anat Bar-Shira, et al.Neurology|August 22, 2022
Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S VariantRachel Saunders-Pullman, Roberto Angel Ortega, Cuiling Wang, et al.Journal of Parkinson'S Disease|December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialM Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.Neurorehabilitation|May 17, 2021
Multidisciplinary intensive outpatient rehabilitation program for patients with moderate-to-advanced Parkinson's diseaseNoa Cohen, Yael Manor, Yitzhak Green, et al.Frontiers in Molecular Neuroscience|September 19, 2024
A novel super-resolution microscopy platform for cutaneous alpha-synuclein detection in Parkinson's diseaseOfir Sade, Daphna Fischel, Noa Barak-Broner, et al.Movement Disorders Clinical Practice|June 5, 2025
High Genetic Diagnostic Yield for Patients with Rare Movement Disorders at a Single-Center Neurogenetics ClinicDvir Penn, Yam Amir, Gil Ben David, et al.Annals of Clinical and Translational Neurology|September 25, 2015
GBA mutations are associated with Rapid Eye Movement Sleep Behavior DisorderZiv Gan-Or, Anat Mirelman, Ronald B Postuma, et al.Movement Disorders : Official Journal of the Movement Disorder Society|May 6, 2021
Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine LearningAnat Mirelman, Mor Ben Or Frank, Michal Melamed, et al.Human Molecular Genetics|March 4, 2010
Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humansSuzanne Lesage, Etienne Patin, Christel Condroyer, et al.Movement Disorders : Official Journal of the Movement Disorder Society|July 27, 2019
Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controlsIlir Agalliu, Roberto A Ortega, Marta San Luciano, et al.Pageof 41